Akebia Therapeutics, Inc. Common Stock (AKBA) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. With a year-over-year growth in debt of 247.44%, Akebia Therapeutics Inc's debt growth rate surpasses 93.97% of about US stocks. In depth view into AKBA (Akebia Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. 4.0500 -0.06 (-1.46%)Pre-Market: 4:58AM EST. Find real-time AKBA - Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Sign Up. Akebia Therapeutics Inc AKBA Morningstar Rating Rating as of Feb 9, 2021. Real-time trade and investing ideas on Akebia Therapeutics AKBA from the largest community of traders and investors. Akebia Therapeutics NASDAQ Updated Feb 20, 2021 12:54 AM. Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know. Feb-24-20 08:00AM : Akebia Therapeutics to Report Fourth Quarter and Full-Year 2019 Financial Results and Discuss Recent Business Highlights . Akebia Therapeutics Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time AKBA stock price. 6 Wall Street analysts that have issued a 1 year AKBA price target, the average AKBA price target is $10.17, with the highest AKBA stock price forecast at $18.00 and the lowest AKBA stock price forecast at $3.00. View today's stock price, news and analysis for Akebia Therapeutics Inc. (AKBA). Their average twelve-month price target is $10.29, predicting that the stock has a possible upside of 123.12%. Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More, Akebia Falls as Vadadustat Fails to Meet Safety Endpoint, Top Analyst Upgrades and Downgrades: Akebia, Broadcom, DocuSign, Lululemon, NextEra, Overstock.com, Shopify, Wayfair and More, Implied Volatility Surging for Akebia (AKBA) Stock Options, Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates, Encompass Health Continues to Strengthen Presence in Florida. Intraday data delayed at least 15 minutes or per exchange requirements. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials … Visit a quote page and your recently viewed tickers will be displayed here. All rights reserved. AKBA’s announcement was unexpected and the sudden plunge of its stock price reflects that. … As of 2021 February 22, Monday current price of AKBA stock is 4.435$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception). , 1D Long. Currency in USD, Trade prices are not sourced from all markets. Akebia Therapeutics Inc (AKBA) Q1 2020 Earnings Call Transcript Why Akebia Therapeutics Stock Is Crushing It Today 2 Small-Cap Stocks That Could Double Your Money Akebia Therapeutics, Inc. has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame. DOW 0.00%. Log in to see them here or sign up to get started. Create a list of the investments you want to track. akba $4.47 $0.16 3.7% Price as of February 19, 2021, 7:05 p.m. EST View Interactive AKBA Charts Akebia Therapeutics (AKBA) Stock Price, Quote & News | Stock Analysis Home » Stocks » AKBA Akebia Therapeutics, Inc. (AKBA) Stock Price: $4.61 USD -0.27 (-5.44%) AKBA: Get the latest Akebia Therapeutics stock price and detailed information including AKBA news, historical charts and realtime prices. View the real-time AKBA price chart on Robinhood and decide if you want to buy or sell commission-free. Its products include Auryxia and Vadadustat. Meritage Homes CEO Phillippe Lord Joins Company’s Board of Directors, American Airlines Names Adriane M. Brown to Its Board of Directors, Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGM - NasdaqGM Real Time Price. Entry level $4.41 = target price $5.14 Average analysts price target $14.86 | Buy Company profile Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The change will be -34.514 %. Subscriber Agreement & Terms of Use, By using this site you agree to the Is the Options Market Predicting a Spike in Akebia (AKBA) Stock? You can buy and sell Akebia Therapeutics (AKBA) stock and options and many more … Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? Since then, AKBA stock has decreased by 33.6% and is now trading at $4.61. AKBA Stock Summary. Get the latest Akebia Therapeutics Inc (AKBA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Copyright © 2021 MarketWatch, Inc. All rights reserved. AKBA - Akebia Therapeutics Inc Stock quote - CNNMoney.com Markets Get Akebia Therapeutics, Inc.'s stock price today. AKBA | Complete Akebia Therapeutics Inc. stock news by MarketWatch. Barron's also provides information on historical stock ratings, target prices… The Akebia Therapeutics stock price may drop from 4.435 USD to 2.904 USD. Do Options Traders Know Something About Akebia (AKBA) Stock We Don't? © 2021 Verizon Media. Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. Historical and current end-of-day data provided by FACTSET. Get the latest Akebia Therapeutics, Inc. AKBA detailed stock quotes, stock data, Real … Akebia Therapeutics Inc's number of analysts covering the stock is higher than 77.93% of stocks in the small market cap category. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. AKBA. The Akebia Therapeutics stock price gained 3.02% on the last trading day (Friday, 19th Feb 2021), rising from $4.31 to $4.44. The volatility of Akebia Therapeutics Inc's share price is greater than that of 95.73% US stocks with at least 200 days of trading history. 7 Wall Street analysts have issued ratings and price targets for Akebia Therapeutics in the last 12 months. Stock analysis for Akebia Therapeutics Inc (AKBA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. S&P 500 0.00%. AKBA stock news . Start planning now: 4 tips for booking the vacation of your life, Burst pipes, flooded homes: Get the most out of your homeowners insurance after a winter storm, Bitcoin drops further below key $50,000 level after Yellen calls it ‘extremely inefficient’, ‘Big Short’ investor Michael Burry warns stimulus may stoke inflation, Tesla shares fall below S&P 500 entry level in premarket trade, Standard Life Aberdeen sells brand to Phoenix, U.K. unemployment rises at end 2020 amid COVID-19, Total sells 50% stakes in renewables portfolios, Allied Universal makes final, $5.34B bid for G4S, InterContinental Hotels swings to 2020 loss, Akebia Therapeutics downgraded to underweight from neutral at J.P. Morgan, Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho, Akebia Therapeutics started at overweight with $12 stock price target at J.P. Morgan, Akebia Therapeutics started at outperform with $18 stock price target at Raymond James, Akebia and Keryx expect deal to close by year-end, Akebia and Keryx say deal will create company with pro forma equity value of about $1.3 bln, Akebia Therapeutics and Keryx Biopharmaceuticals to merge in all-stock deal, Akebia Therapeutics' stock soars 78% to lead Nasdaq gainers after positive trial results, Akebia's shares jump on late-stage clinical trial results for kidney disease drug, Akebia shares jump on expanded anemia drug deal with Otsuka, Akebia Shares Could More Than Double in a Year, Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release, David Abrams Punctures TransMedics Group Position, Biogen, 3D Systems, Duke Energy, Ford and More of Friday Afternoon’s Analyst Calls, Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. All Akebia Therapeutics Inc. historial stock quotes by MarketWatch. The price has been going up and down for this period, and there has been a 14.73% gain for the last 2 weeks. Cancel. All quotes are in local exchange time. Intraday Data provided by FACTSET and subject to terms of use. Trending now. The upside potential (average analyst target price relative to current price) of AKBA is greater than 81.31% of all US stocks. Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of LeAnne M. Zumwalt to its Board of Directors, effective February 16, 2021. Simply Wall St. Feb-25-20 09:41AM : Is the Options Market Predicting a Spike in Akebia Therapeutics (AKBA) Stock? Akebia Therapeutics, Inc. Common Stock (AKBA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Ms. Zumwalt was most recently Group Vice President, Government Affairs at DaVita Inc., one of the largest providers of dialysis and kidney care services in the United States. Cookie Notice (). View the latest Akebia Therapeutics Inc. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. View Akebia Therapeutics, Inc. AKBA investment & stock information. According to . The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). For the best MarketWatch.com experience, please update to a modern browser. AKBA stock quote, chart and news. Have Watchlists? Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year 2020 ended December 31, 2020, on Thursday, February 25, 2021, before the opening of the financial markets. There are currently no items in this Watchlist. Rooms Shows Rankings Earnings Calendar Shop. A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. Get today's Akebia Ther stock price and latest AKBA news as well as Akebia Ther real-time stock quotes, technical analysis, full financials and more. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Akebia Therapeutics against related stocks people have also bought. Log In. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Some bargain investors may see … View historical AKBA stock price data to see stock performance over time. One Thing To Remember About The Akebia Therapeutics, Inc. (NASDAQ:AKBA) Share Price. View which stocks have been most impacted by COVID-19. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 19 newly-hired employees options to purchase an aggregate of 161,000 shares of Akebia's common stock on January 29, 2021, as inducements material to each such employee's entering into employment with Akebia. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. During the day the stock fluctuated 3.91% from a day low at $4.35 to a day high of $4.52. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. Akebia Therapeutics 4.44 0.13 (3.02%) Watch. Privacy Notice, and Discover historical prices for AKBA stock on Yahoo Finance. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA. Zacks-10.91%. Will AKBA stock price grow / rise / go up? AKBA … View daily, weekly or … The average analyst price target of AKBA is higher than 14.03% of all US stocks. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The high price target for AKBA is $18.00 and the low price target for AKBA is $3.00. NASDAQ 0.00%. Price/Cash Flow: Latest closing price divided by the last 12 months revenue/cash flow per share. Something went wrong while loading Watchlist. View real-time stock prices and stock quotes for a full financial overview. Akebia Therapeutics (AKBA) Gets a Buy Rating from Mizuho Securities, Needham Releases a Buy Rating on Akebia Therapeutics (AKBA), Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates, Seth Klarman Axes Akebia Therapeutics Stake From Portfolio, Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session. Bullishcharts Nov 22, 2019. This browser is no longer supported at MarketWatch.